Country Access Report
Bahrain maintains strict national controls on narcotics and psychotropic substances administered and enforced through the National Health Regulatory Authority (NHRA) and criminal law. Traditional psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are treated as controlled substances with no authorized medical use outside approved research; ketamine is available and used in medical settings as an anesthetic and for off‑label psychiatric use within regulated health facilities. There is no public, nation‑wide reimbursement program or NHRA‑published marketing approval (as of Feb 20, 2026) for branded intranasal esketamine (Spravato) in Bahrain’s publicly available regulatory records.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Currently classified as a strictly controlled substance under Bahrain’s narcotics and psychotropic substances framework, with no authorized medical use outside of approved clinical research. This legal posture is enforced under Bahrain’s narcotics law and NHRA regulatory framework which reserves tightly controlled status for illicit psychoactive substances and permits only tightly regulated medical/scientific research subject to ministerial/NHRA approval. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, importation, manufacture, or trafficking of MDMA attract severe criminal penalties under Bahraini narcotics law; any clinical use would require explicit NHRA and ministerial authorization. [1] [2]
Compound Access
There is no publicly available NHRA record or formal NHRA/Ministry of Health publication indicating marketing authorization or reimbursement for intranasal esketamine (Spravato) in Bahrain as of Feb 20, 2026; NHRA handles medicine registration and the regulation of narcotic/psychotropic substances and maintains the authoritative register for permitted medicinal products. Esketamine is therefore not recognized in publicly available Bahraini regulatory listings as an approved, reimbursed treatment; importation, use, or provision would require NHRA approval and prescribing within authorized health facilities. [1] [2]
Note: ketamine (the racemate) is a long‑established anesthetic and may be supplied to hospitals under medical controls, but branded esketamine preparations require explicit product registration and local reimbursement decisions which are not present in the NHRA public listings reviewed.
Compound Access
Ketamine is a controlled medicine that is legally used in Bahrain within licensed medical facilities for anesthesia and other accepted clinical indications under NHRA regulation; its distribution and clinical use are subject to the registration, prescribing and hospital supply controls administered by NHRA and the laws governing narcotic/psychotropic substances. The NHRA is the regulatory authority for medicines and for setting conditions on controlled substances and the Medicines/Health Insurance laws apply to clinical provision of hospital therapies. Publicly available Bahraini law and NHRA materials indicate controlled but permitted medical use rather than an outright prohibition. [1] [2] [2]
Reimbursement/coverage note: Bahrain’s Health Insurance Law (Law No. 23 of 2018) and hospital financing arrangements govern coverage for inpatient procedures and therapies provided in the public system, but there is no NHRA-published, compound‑specific national reimbursement schedule for ketamine psychiatric use; supply and payment depend on clinical setting (public hospital vs private clinic) and the usual hospital/pharmacy procurement and insurance arrangements.
Compound Access
Compound Access
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no regulatory pathway in Bahrain for routine clinical ibogaine therapy outside tightly controlled research authorization. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Use or importation of ayahuasca (containing DMT) would fall under prohibitions on psychotropic substances unless otherwise authorised by NHRA for research. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and peyote‑type materials are prohibited under Bahraini narcotics controls absent specific NHRA/ministerial research authorization. [1]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamine psychedelics such as 2C‑series compounds are covered by Bahraini psychotropic controls and criminal law. [1] [2]
Last updated 2 Mar 2026. Source links come from the medical access guide.